BCV
VIR icon

Banque Cantonale Vaudoise’s Vir Biotechnology VIR Stock Holding History

Banque Cantonale Vaudoise’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,484
Closed -$58K – 1232
2023
Q1 		$58K Hold
2,484
– – ﹤0.01% 934
2022
Q4 		$63K Hold
2,484
– – ﹤0.01% 924
2022
Q3 		$48K Hold
2,484
– – ﹤0.01% 997
2022
Q2 		$63K Buy
+2,484
New +$58K ﹤0.01% 962

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Banque Cantonale Vaudoise's VIR Position: Q2 2023 in Review

Banque Cantonale Vaudoise sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 2,484 shares — an estimated $58K sold.

Banque Cantonale Vaudoise first reported a position in VIR in Q2 2022 and held it in 4 quarters. The position peaked at $63K in Q4 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • Banque Cantonale Vaudoise reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 2,484 Vir Biotechnology shares in Q2 2023, an estimated $58K.
  • Banque Cantonale Vaudoise first reported a position in Vir Biotechnology in Q2 2022 and held it in 4 quarters.
  • Banque Cantonale Vaudoise's Vir Biotechnology position peaked at $63K in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2023, filed 9 Aug 2023.